Patent · US Active

Modified soluble FGF receptor Fc fusions with improved biological activity

US8119770B2 · kind B2 · utility

17Cited by

9References

20Claims

0Family size

Assignee

AVENTIS PHARMA S.A. · FR

Inventors

Francis Blanche · Paris, FR
Beatrice Cameron · Paris, FR
Mark S. Nesbit · Paris, FR
Sylvie Sordello · Paris, FR
Céline NICOLAZZI · Choisy-le-Roi, FR
Marc Trombe · Paris, FR

Key dates

Filing date	Nov 28, 2007
Grant date	Feb 21, 2012
Priority date	—
Expiry date	Aug 11, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.